3-MeO-PCE
3-methoxyeticyclidine
Viewing r1 — Apr 28, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3-MeO-PCE (3-methoxyeticyclidine) is a synthetic dissociative of the arylcyclohexylamine class. It is a close structural analog of phencyclidine, distinguished by stronger serotonergic activity. 3-MeO-PCE is an NMDA receptor antagonist, producing its effects by blocking glutamate signaling while simultaneously inhibiting serotonin reuptake.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, phencyclidine, methoxetamine +3 moreketamine, phencyclidine, methoxetamine, dextromethorphan, 3-MeO-PCP, 2F-DCK show less
3-MeO-PCE emerged on European research chemical markets around 2010 with no pharmaceutical or academic origin, first reported to the EU Early Warning System by the United Kingdom.[2] Pharmacological profiling followed in 2013,[1] with the first peer-reviewed synthesis published in 2016.[3] It remains unscheduled internationally, though several countries have enacted individual bans.
Subjective effects include dissociation, euphoria, analgesia, cognitive distortion, and depersonalization. The experience is defined by an unusual warmth and stimulant-like energy layered onto classical dissociation — a combination that distinguishes it from the sedating detachment of ketamine or the cold disconnection of PCP. Mania, delusional thinking, and compulsive redosing are characteristic unsought effects.
3-MeO-PCE substitutes for PCP in animal drug discrimination assays, confirming substantial abuse liability, and the 3-methoxy substitution confers increased acute lethality in mice.[4] Dual NMDA antagonism and serotonin reuptake inhibitor elevates psychosis and mania risk beyond that of purely glutamatergic dissociatives.[1] No controlled human studies exist; the evidence rests on receptor binding data, one metabolic study, one animal toxicology study, and a single polydrug fatality report.[5]
History[edit]
Origins
3-MeO-PCE descends from eticyclidine (PCE), a dissociative anesthetic developed by Parke-Davis in the 1970s as a more potent alternative to phencyclidine.[6] PCE was abandoned after ketamine proved safer and better-tolerated, and was placed in Schedule I of the 1971 UN Convention on Psychotropic Substances.[2] 3-MeO-PCE itself has no pharmaceutical history — it emerged from clandestine synthesis exploiting published structure-activity relationships, appearing on research chemical markets before any academic literature described it.
Research timeline
The United Kingdom reported 3-MeO-PCE to the EU Early Warning System in 2010, the first formal documentation of the compound on the European drug market.[2] Pharmacological profiling came in 2013 through the NIMH Psychoactive Drug Screening Program,[1] and Wallach et al. published the first peer-reviewed synthesis and analytical characterization in 2016.[3] The first published fatality involving 3-MeO-PCE — a polydrug case in France — was reported in 2021,[5] followed in 2024 by the compound's only metabolic study[7] and mouse toxicology data demonstrating lethality and PCP-like abuse liability.[4]
Modern status
No clinical trials have been registered and no therapeutic rationale has been proposed for 3-MeO-PCE. The compound circulates on research chemical markets and is controlled in several countries — including the United Kingdom, Canada, Germany, and Sweden — primarily through structural analog or blanket new psychoactive substance legislation rather than specific scheduling. It is not controlled under any international drug convention.
The name follows standard research chemical nomenclature: "3-MeO" denotes the methoxy group at the meta position of the phenyl ring, and "PCE" abbreviates the parent compound eticyclidine (phenylcyclohexyl ethylamine). Among dissociative users, the compound has a reputation for being more manic and unpredictable than most other arylcyclohexylamines — a characterization consistent with its unusual dual-target pharmacology. No widely recognized street names have emerged.
Chemistry[edit]
Structural class
3-MeO-PCE belongs to the arylcyclohexylamine family, the structural class that includes phencyclidine, ketamine, and methoxetamine. The core scaffold is a cyclohexane ring bearing both an aryl group and an amine nitrogen. In 3-MeO-PCE, the phenyl ring carries a methoxy group at the meta position, and the nitrogen bears an ethyl group — contrasting with the piperidine ring of PCP or the methyl group of ketamine.[3]
Molecular properties
| Molecular formula | C₁₅H₂₃NO |
| Molecular weight | 233.35 g/mol |
The molecule features a quaternary carbon at C1 of the cyclohexane ring, bonded to the 3-methoxyphenyl group and an N-ethylamino group.[3]
Stereochemistry
3-MeO-PCE is achiral. The quaternary carbon at C1 bears two equivalent methylene chain segments from the symmetric cyclohexane ring, making it a non-stereogenic center. The compound exists as a single molecular species with no enantiomers — unlike Methoxetamine, which has a chirality center adjacent to its ketone carbonyl.
Structure-activity relationships
The 3-methoxy substitution on the PCE scaffold is pharmacologically consequential. Compared to parent eticyclidine, the meta-methoxy group preserves high NMDA potency while conferring the strongest SERT affinity among profiled arylcyclohexylamines.[1] The same substitution increases acute toxicity in mice relative to unsubstituted PCE.[4] The ethyl group on nitrogen — rather than the methyl of ketamine or piperidine ring of PCP — contributes to the compound's distinct pharmacological profile within the class.
Pharmacology[edit]
Mechanism of action
3-MeO-PCE blocks the NMDA glutamate receptor at the phencyclidine binding site inside the ion channel.[1] This blockade is use-dependent — the channel must first be opened by glutamate before the drug can enter and obstruct ion flow.[8][1] The resulting disruption of glutamate signaling produces the characteristic dissociative effects: altered sensory processing, analgesia, perceptual distortion, and dose-dependent disconnection of consciousness from bodily input.[9][10]
At the NMDA receptor, 3-MeO-PCE is approximately as potent as PCP itself, roughly three times stronger than methoxetamine, and ten times stronger than ketamine.[1]
The compound's second major action is inhibition of the SERT — the strongest such activity among arylcyclohexylamines profiled in the same assay panel, exceeding 3-MeO-PCP, methoxetamine, and PCP.[1] This serotonin reuptake inhibitor is the likely basis for the stimulant-adjacent quality and elevated mania risk that set 3-MeO-PCE apart from purely glutamatergic dissociatives.
3-MeO-PCE also shows moderate sigma-2 receptor activity but negligible sigma-1 receptor binding[1] — a sharp contrast with 3-MeO-PCP, which has potent sigma-1 affinity. Dopamine transporter activity is weak.[11]
Pharmacokinetics
No human pharmacokinetic studies have been published. Oral bioavailability, peak blood levels, plasma half-life, and protein binding are entirely uncharacterized in humans.
The only metabolic study used human liver microsomes, zebrafish, and two forensic human urine samples, identifying 14 metabolites.[7] The primary metabolic pathways are hydroxylation (the dominant route), removal of the methoxy group, removal of the ethyl group from the nitrogen, and introduction of double bonds in the cyclohexane ring, followed by glucuronidation and sulfation.[7]
By structural analogy with Ketamine, liver enzymes CYP3A4 and CYP2B6 are the expected primary metabolizers,[12][9] though direct confirmation is lacking. The dominance of hydroxylation and N-dealkylation as Phase I routes is consistent with metabolic patterns observed for Methoxetamine.[13][7]
Neuroscience[edit]
Where it acts
3-MeO-PCE disrupts glutamate signaling at connections between the thalamus and cortex and between cortical regions. By blocking NMDA receptors on inhibitory interneurons in the prefrontal cortex, the compound paradoxically increases excitatory neuron firing — a glutamate surge that produces disordered cortical activation, manifesting as perceptual distortion and psychosis-like symptoms.[14][8] Simultaneously, serotonin reuptake inhibitor raises synaptic serotonin levels, potentially amplifying cortical excitation through 5-HT₂A receptor activation.[1] This dual disruption — glutamatergic disinhibition compounded by serotonergic potentiation — is the proposed basis for the elevated psychosis risk that distinguishes 3-MeO-PCE from ketamine or dextromethorphan.
Why it matters
The dissociative state is best understood as a functional disconnection: sensory input reaches the brain but fails to integrate with higher-order processing, producing the subjective experience of detachment from body and environment.[9][10] ketamine's antidepressant mechanism involves a compensatory signaling cascade triggered by NMDA blockade, leading to rapid new synapse formation in prefrontal cortex.[8] Whether 3-MeO-PCE engages this same neuroplasticity pathway is unknown — its higher NMDA potency and concurrent serotonin activity could either enhance or disrupt the process.
Substance-induced psychotic disorder has been documented for the close structural analog 3-MeO-PCP, with brain imaging showing altered metabolic activity consistent with NMDA-antagonist-induced changes.[15][14] Whether 3-MeO-PCE produces the same pattern, whether sigma-2 activity contributes to brain changes at high or repeated doses, and whether chronic use produces the neurotoxic damage observed with other high-potency NMDA antagonists remain untested.
Subjective Effects[edit]
3-MeO-PCE produces a dissociative experience with a distinctly stimulant-adjacent edge — a warm, energized detachment rather than the sedating blankness of ketamine or the heavy immobilization of high-dose dextromethorphan. At lower doses, effects center on mood lift, physical lightness, and mild perceptual shifts. As dose increases, dissociation deepens into depersonalization, cognitive fragmentation, and grandiose or delusional thinking. Set and setting exert strong influence, and the slow oral onset creates a pronounced redosing hazard — the experience may feel negligible at the point a second dose is most tempting.
Compared to Ketamine, 3-MeO-PCE is longer-acting, more stimulating, and carries a markedly higher risk of mania. Relative to 3-MeO-PCP, which shares the 3-methoxy substitution but recruits different secondary receptor targets, 3-MeO-PCE is reported as somewhat shorter and smoother — though both carry pronounced psychosis risk beyond most dissociatives.
Effect Grid
At common doses, the full dissociative character emerges: pronounced depersonalization and derealization, significant cognitive distortion with disrupted linear thinking, euphoria, and a sense of detached observation of one's own experience. Sensory perception is markedly altered — sounds may echo or become layered, visual field may develop a dreamlike or synthetic quality. The stimulant-adjacent component remains present as physical and mental energy.
Physical effects include clear analgesia, tachycardia, pupil dilation, and mild motor impairment. Nausea is uncommon but possible, particularly on oral dosing.
Functional impairment is significant. The experience typically lasts 5–7 hours orally. The mania and psychosis risk that distinguishes 3-MeO-PCE from other dissociatives begins to manifest at this dose range, particularly with repeated use or pre-existing vulnerability.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Visual drifting · Touch enhancement · Auditory distortion · Depth perception distortion · Ganzfeld effect · Tracers · Visual haze / noise · Touch suppression · Music enhancement · Visual acuity suppression · Auditory enhancement · Auditory misinterpretation · Auditory suppression · Brightness alteration · Color alteration · Color enhancement · After-images · Environmental patterning · Visual acuity enhancement · Synesthesia · Visual processing suppression · Auditory hallucinations · External hallucinations · Visual scenery slicing · Internal hallucinations · Environmental orbism / cubism · Olfactory hallucination
Depth perception distortion · Ganzfeld effect · Tracers · Visual haze / noise · Touch suppression · Music enhancement · Visual acuity suppression · Auditory enhancement · Auditory misinterpretation · Auditory suppression · Brightness alteration · Color alteration · Color enhancement · After-images · Environmental patterning · Visual acuity enhancement · Synesthesia · Visual processing suppression · Auditory hallucinations · External hallucinations · Visual scenery slicing · Internal hallucinations · Environmental orbism / cubism · Olfactory hallucination
Nystagmus (eye wobbles) · Bodily lightness · Appetite suppression · Body high · Body schema distortion · Pupil dilation · Wakefulness · Spontaneous body sensations · Tactile euphoria · Restlessness · Dry mouth · Insomnia · Laughter fits · Muscle relaxation · Physical fatigue · Sedation · Dehydration sensation · Excessive sweating · Heart rate perception changes · Vasoconstriction · Abnormal heartbeat · Respiratory depression · Nausea · Sexual arousal enhancement · Nausea suppression · Vomiting · Increased urination · Motor control enhancement · Bodily dissociation · Seizure threshold reduction
Body high · Body schema distortion · Pupil dilation · Wakefulness · Spontaneous body sensations · Tactile euphoria · Restlessness · Dry mouth · Insomnia · Laughter fits · Muscle relaxation · Physical fatigue · Sedation · Dehydration sensation · Excessive sweating · Heart rate perception changes · Abnormal heartbeat · Respiratory depression · Nausea · Sexual arousal enhancement · Nausea suppression · Vomiting · Increased urination · Motor control enhancement · Bodily dissociation · Seizure threshold reduction
Thought disorganization · Cognitive euphoria · Memory suppression · Cognitive fatigue · Focus suppression · Information processing suppression · Memory fragmentation · Thought loops · Immersion enhancement · Analysis suppression · Humor enhancement · Introspection enhancement · Delusions of sobriety · Language suppression · Motivation suppression · Suggestibility enhancement · Thought acceleration · Conceptual thinking · Thought deceleration · Pattern recognition suppression · Creativity enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Cognitive fatigue · Focus suppression · Information processing suppression · Memory fragmentation · Thought loops · Immersion enhancement · Analysis suppression · Humor enhancement · Introspection enhancement · Language suppression · Motivation suppression · Suggestibility enhancement · Thought acceleration · Conceptual thinking · Thought deceleration · Pattern recognition suppression · Creativity enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Anxiety · Emotional lability · Empathy suppression · Irritability · Dysphoria
Dysphoria
Communication suppression · Craving · Ego inflation · Social disconnection · Sociability suppression · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Sociability suppression · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Timeline
First alerts appear as subtle mood shift and mild bodily awareness. Effects may be delayed by food intake. The slow onset is a common redosing trap — effects can take up to 90 minutes to manifest.
Dissociation builds gradually alongside increasing stimulation and euphoria. Sensory perception begins to shift — sounds may take on a processed quality. Mild motor impairment and analgesia emerge.
Maximum dissociation, cognitive distortion, and euphoria. At common doses, depersonalization and altered sensory processing dominate. The stimulant-adjacent quality — physical energy, talkativeness — is most apparent during peak.
Intensity diminishes from peak but dissociative and cognitive effects persist at a sustained level. Mania-like states or delusional thinking, if present, may continue or emerge during this phase.
Gradual return toward baseline cognition and sensory processing. Residual stimulation and mood elevation may persist. Motor coordination recovers before cognitive clarity.
Residual mood changes, mild cognitive fog, and possible lingering stimulation lasting into the following day. Sleep may be difficult for several hours after subjective resolution.
⚠ Do not drive or operate heavy machinery for at least 12 hours after dosing, or until a full night of sleep has been obtained.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
Acute toxicity
No lethal dose, therapeutic index, or safe exposure limit has been established for 3-MeO-PCE in any species. Animal testing showed that the 3-methoxy substitution on the PCE scaffold increased acute lethality in mice compared to unsubstituted PCE, PCP, or ketamine at equivalent dose ranges.[4]
Fatal human case
One polydrug fatality involving 3-MeO-PCE has been published.[5] The individual was found dead alongside three powders (2F-DCK, 3-MeO-PCE, and 5-MeO-DMT), with amphetamine and cocaine also detected. The cause of death was respiratory depression, attributed primarily to 2F-DCK, with 3-MeO-PCE as a contributing factor. Hair analysis revealed months of escalating novel psychoactive substance use. 3-MeO-PCE cannot be identified as the sole lethal agent in this polydrug context.
Heart and circulation
Increased heart rate and elevated blood pressure are class effects of arylcyclohexylamines, arising from stimulation of the sympathetic nervous system.[16][17] No 3-MeO-PCE-specific cardiovascular data have been published.
Urinary tract damage
Chronic heavy Ketamine use causes bladder damage through a mechanism independent of NMDA blockade.[18] Whether 3-MeO-PCE shares this direct toxic effect on bladder tissue is unknown. Structural similarity to ketamine warrants caution with chronic use, but the risk cannot be quantified without substance-specific data.
Psychological Risks
Psychosis, mania, delusions, and paranoia represent the most prominent safety signal for 3-MeO-PCE. User communities consistently identify this compound as carrying higher mania and psychosis risk than most dissociatives, including Ketamine and methoxetamine.
This risk has a clear mechanistic basis: potent NMDA antagonism combined with strong serotonin reuptake inhibitor produces both glutamatergic disinhibition and serotonergic amplification — a dual mechanism expected to drive psychotomimetic effects beyond those of purely glutamatergic dissociatives.[1]
Substance-induced psychotic disorder with persistent cognitive impairment has been documented for the close structural analog 3-MeO-PCP, with brain imaging confirming altered metabolic activity.[15] Comparable risk is expected for 3-MeO-PCE given shared NMDA antagonism and even stronger SERT inhibition. Personal or family history of psychosis, mania, bipolar disorder, or schizophrenia significantly elevates vulnerability.
Additional neurological effects observed in PCP-class intoxications include involuntary eye movements, loss of coordination, slurred speech, memory loss, delirium, and agitation.[19][20]
Tolerance & Dependence
No formal tolerance or dependence studies have been published for 3-MeO-PCE. User reports indicate tolerance develops with repeated use.citation needed
The tolerance mechanism is presumed to involve compensatory NMDA receptor changes in response to sustained channel blockade — the same process underlying tolerance to Ketamine and phencyclidine. Cross-tolerance with other dissociatives (Ketamine, PCP, Methoxetamine, dextromethorphan) is expected through the shared NMDA receptor target.
3-MeO-PCE substituted for PCP in drug discrimination assays, confirming PCP-like reinforcing properties and substantial abuse liability.[4] PCP produces both physical and psychological dependence in humans;[21] analogous dependence potential is expected. Compulsive redosing is reported by users.citation needed
Drug Interactions
All interaction data is inferred from class pharmacology and close analog case reports. No published human interaction study exists for 3-MeO-PCE.CNS depressants (opioids, benzodiazepines, alcohol, GHB, other dissociatives): Additive or synergistic respiratory depression. The published polydrug fatality involved 2F-DCK as the primary lethal agent combined with 3-MeO-PCE, 5-MeO-DMT, amphetamine, and cocaine — death resulted from respiratory depression.[5]
Serotonergic drugs (SSRIs, SNRIs, MAOIs): 3-MeO-PCE's strong serotonin transporter inhibition creates risk of serotonin syndrome when combined with other serotonergic agents.[1] A fatal case involving a closely related arylcyclohexylamine combined with an SNRI demonstrates the lethal potential of such combinations.[22] MAOIs present the highest theoretical risk.
Stimulants (amphetamines, cocaine, MDMA): Compounded cardiovascular strain and exacerbated mania risk. Both stimulant classes were detected in the published polydrug fatality.[5]
Lithium: Lowered seizure threshold and potential exacerbation of manic episodes.safety citation needed
Other dissociatives: Additive NMDA antagonism with unpredictable dose-response — cross-tolerance makes titration unreliable.
Contraindications
Psychotic disorders and bipolar disorder: Strongly contraindicated. The elevated mania and psychosis risk — grounded in dual NMDA antagonism and serotonin reuptake inhibition — makes this compound particularly dangerous for individuals with personal or family history of psychosis, mania, bipolar disorder, or schizophrenia.[15]
Breathing difficulties: Any condition compromising baseline respiratory function increases overdose risk, confirmed by the respiratory depression mechanism in the published polydrug fatality.[5]
Liver impairment: 3-MeO-PCE is metabolized by the liver.[7] Impaired liver function may prolong drug exposure and increase toxicity risk.
Seizure disorders: Arylcyclohexylamines lower seizure threshold as a class effect.[16] Contraindicated for individuals with epilepsy or those taking medications that lower seizure threshold.
Serotonergic medication: Strong serotonin transporter inhibition makes combination with SSRIs, SNRIs, or MAOIs contraindicated due to serotonin syndrome risk.[1][22]
Pregnancy and breastfeeding: No reproductive toxicity data exist. Contraindicated on precautionary grounds given NMDA receptor involvement in brain development.safety citation needed
Harm Reduction[edit]
Forms & Identification
3-MeO-PCE circulates primarily as a white crystalline powder sold through research chemical vendors. Arylcyclohexylamines are frequently mislabeled or cross-contaminated — compounds in this class can be visually indistinguishable from one another. Reagent testing can differentiate broad substance classes but cannot reliably distinguish between closely related arylcyclohexylamines; quantitative analysis through a laboratory testing service provides the only reliable identification.
Volumetric dosing or an analytical balance accurate to the milligram is essential — 3-MeO-PCE is active at low doses and small measurement errors can produce meaningfully different effects.
Guidelines
- Test every batch with reagent kits and, where possible, a laboratory testing service.
- Weigh doses carefully with a milligram-accurate scale — never estimate by eye.
- Start at the low end of reported dose ranges, especially with a new batch or no prior experience with this compound.
- Set a firm time boundary before dosing: do not redose for at least 2–3 hours orally or 90 minutes insufflated, regardless of perceived intensity.
- Have a sober, trusted companion present who understands the compound's mania and psychosis risk.
- Keep the environment calm, familiar, and free of responsibilities. Remove car keys and secure access to balconies or windows.
- Stay hydrated but do not force fluids. Eat a light meal several hours before dosing.
- Write down the time and amount of each dose — under dissociative effects, accurate recall may be impaired.
Set & Setting
3-MeO-PCE is unusually sensitive to context. The stimulant-adjacent character and elevated mania risk mean that high-energy, chaotic, or unfamiliar environments increase the likelihood of agitation, paranoid thinking, and impulsive behavior. A calm, controlled environment with a trusted sober companion is strongly recommended, particularly at higher doses or during initial experiences.
The slow oral onset — potentially exceeding 60 minutes — is a well-documented redosing trap. Effects may seem negligible at the point when the temptation to take more is strongest. Decide on a dose before beginning and commit to it.
Aftercare & integration. Dissociative experiences can leave residual feelings of detachment, unreality, or emotional suppression that persist for hours to days after acute effects resolve. Re-grounding practices help: physical contact with familiar textures, walking outdoors, gentle exercise, warm food, and conversation with trusted people.
Sleep disruption is common following 3-MeO-PCE use. Prioritize rest, avoid stimulants (including caffeine) in the recovery window, and allow at least one full night's sleep before making significant decisions. If unusual thought patterns, grandiosity, or paranoid thinking persist beyond 48 hours, consult a healthcare professional — persistent symptoms may indicate substance-induced mania or psychosis requiring clinical attention.
Recovery & Support
Compulsive redosing is reported with 3-MeO-PCE. If use has become frequent, escalating, or difficult to stop, professional support is available. Dissociative-specific dependency is less well served by mainstream addiction resources, but general substance use disorder programs, harm reduction organizations, and peer support communities can help.
Tapering rather than abrupt cessation is advisable for heavy users, as NMDA adaptations from sustained use may produce rebound effects. A healthcare provider familiar with novel psychoactive substances can guide this process.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable effects include mild confusion, nausea, and elevated heart rate. Seek immediate help if any of the following occur:
- Loss of consciousness or unresponsiveness
- Extremely rapid or irregular heartbeat
- Seizure activity
- Severe agitation, violent behavior, or self-harm risk
- Inability to breathe normally
- Psychotic symptoms (paranoid delusions, complete break from reality) that cannot be de-escalated
Immediate steps:
- Call emergency services immediately if the person is unresponsive, seizing, or showing signs of breathing difficulty.
- Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- Do not restrain an agitated person unless there is immediate risk of self-harm or harm to others — restraint can escalate agitation.
- Do not induce vomiting.
- Monitor breathing continuously until help arrives.
What to tell the dispatcher:
Name the substance (3-MeO-PCE, an arylcyclohexylamine dissociative), the estimated amount, the time of ingestion, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
3-MeO-PCE is not controlled under any international drug convention. The parent compound eticyclidine (PCE) is listed in Schedule I of the 1971 UN Convention on Psychotropic Substances,[2] but this does not automatically extend to structural analogs. Most regulatory actions rely on analog or blanket new psychoactive substance provisions rather than specific scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | May be prosecutable under the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption, given structural and pharmacological similarity to PCP (Schedule II). 3-MeO-PCP was placed in Schedule I in June 2025[23] |
| United Kingdom | Banned | Controlled as a structural analog of eticyclidine (Class A under the Misuse of Drugs Act 1971) and/or covered by the Psychoactive Substances Act 2016[23] |
| Canada | Schedule I (CDSA) | All PCP analogues, derivatives, salts, and isomers fall under Schedule I of the Controlled Drugs and Substances Act[23] |
| Germany | Banned | Controlled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) as an arylcyclohexylamine[23] |
| Sweden | Banned | Controlled as a psychoactive substance[23] |
| Switzerland | Banned | Controlled substance[23] |
| Australia | Status unclear | May be covered under state/territory analogue provisions due to structural similarity to PCP/eticyclidine. Specific scheduling not confirmedcitation needed |
| European Union | No EU-wide control | Individual member states have enacted controls independently. Not subject to EU-level scheduling decision |
Analog law considerations
In jurisdictions with analog or blanket new psychoactive substance legislation, legal status depends on interpretation of "substantial similarity" to scheduled parent compounds (PCP, PCE). The 2025 DEA scheduling of 3-MeO-PCP into Schedule I may strengthen analog enforcement arguments against 3-MeO-PCE in the United States. Legal status should be confirmed with jurisdiction-specific legal counsel.
references
- [1]
- [2]
- [3] ^abcdWallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, Brandt SD (2016) Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines — Drug Testing and Analysis doi:10.1002/dta.1861
- [4] ^abcdeShaw HE, Patel DR, Gannon BM, Fitzgerald LR, Carbonaro TM, Johnson CR, Fantegrossi WE (2024) Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents — The Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.123.001942
- [5]
- [6]